Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;48(3):300060520914826.
doi: 10.1177/0300060520914826.

Diagnostic value of serum pepsinogen I, pepsinogen II, and gastrin-17 levels for population-based screening for early-stage gastric cancer

Yaping Wang  1 , Zhiyong Zhu  1 , Zhilan Liu  2 , Zhen Zhao  1 , Xiaohong Xue  2 , Xiaolin Li  2 , Pingying Li  2 , Guanghong Rong  2 , Yingcai Ma  2
Affiliations

Diagnostic value of serum pepsinogen I, pepsinogen II, and gastrin-17 levels for population-based screening for early-stage gastric cancer

Yaping Wang et al. J Int Med Res. 2020 Mar.

Abstract

Objective: Diagnosing gastric cancer (GC) at early stages is important for reducing its mortality. This study evaluated the diagnostic value of serum pepsinogen (PG) I, PGII, and gastrin-17 (G17) levels in screening for early-stage GC.

Methods: Serum levels of PGI, PGII, and G17 were measured in patients with upper digestive tract symptoms or GC family histories, and the PGI to PGII ratio (PGR) was calculated. Receiver operator characteristic curves were used to determine the thresholds of PGI, PGR, and G17 for GC diagnosis.

Results: Among the 949 patients examined by gastroscopy, 13 (1.37%) had GC, including five cases of early-stage GC and eight cases of progressive GC. PGI, PGR, and G17 showed good specificity and sensitivity for early-stage and progressive GC. The optimal thresholds of PGI, G17, and PGR were 71.85 μg/L, 15.65 pmol/L and 5.04 for the diagnosis of early-stage GC, respectively, and were 42.55 μg/L, 20.55 pmol/L, and 2.79 for the diagnosis of progressive GC, respectively.

Conclusion: Combining PG and G17 serum levels with gastroscopy could be a promising approach to screen for early-stage GC.

Keywords: Pepsinogen I (PGI); gastric cancer; gastrin-17 (G17); gastroscopy; pepsinogen II (PGII); screening.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Receiver operating characteristic (ROC) curves for diagnosing gastric cancer (GC). (a) ROC curves of pepsinogen (PG) I and the PGI to PGII ratio (PGR) for diagnosing early-stage GC. (b) ROC curves of gastrin-17 (G17) for diagnosing early-stage GC. (c) ROC curves of PGI and PGR for diagnosing progressive GC. (d) ROC curves of G17 for diagnosing progressive GC.
See this image and copyright information in PMC

References

    1. Huang YK, Yu JC, Kang WM, et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PLoS One 2015; 10: e0142080. - PMC - PubMed
    1. Yamaguchi Y, Nagata Y, Hiratsuka R, et al. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels–the ABC method. Digestion 2016; 93: 13–18. - PubMed
    1. Enomoto S, Maekita T, Ohata H, et al. Novel risk markers for gastric cancer screening: present status and future prospects. World J Gastrointest Endosc 2010; 2: 381–387. - PMC - PubMed
    1. Tu H, Sun L, Dong X, et al. A serological biopsy using five stomach-specific circulating biomarkers for gastric cancer risk assessment: a multi-phase study. Am J Gastroenterol 2017; 112: 704–715. - PubMed
    1. Daugule I, Ruskule A, Moisejevs G, et al. Long-term dynamics of gastric biomarkers after eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2015; 27: 501–505. - PubMed